<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02636088</url>
  </required_header>
  <id_info>
    <org_study_id>2008-006802-40</org_study_id>
    <nct_id>NCT02636088</nct_id>
  </id_info>
  <brief_title>Definitive Chemoradiotherapy and Cetuximab in the Treatment of Locally Advanced Esophageal Cancer</brief_title>
  <acronym>LERFOX-C</acronym>
  <official_title>A Phase II Study With Oxaliplatin + 5-FU + Ceuximab and Radiotherapy for the Treatment of Non-resectable, Locally Advanced But Not Metastatic Cancer of Oesophagus or the Cardia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gabriella Alexandersson von Döbeln</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In patients with esophageal cancer, treatment with curative intent can be given to medically&#xD;
      fit patients without distant metastases. It may consist of chemoradiotherapy or surgery alone&#xD;
      or in combination. Surgery in combination with chemotherapy is another option. For patients&#xD;
      who are not medically fit for surgery or with unresectable invasion in adjacent structures&#xD;
      the only alternative with curative intent is, with current knowledge, definitive&#xD;
      chemoradiotherapy. In the current study the investigators aim to improve prognosis for&#xD;
      patients not suitable for surgery. Patients receive treatment with conventional&#xD;
      chemoradiotherapy (oxaliplatin, fluorouracil and radiotherapy) with the addition of a more&#xD;
      recently developed drug, an antibody called cetuximab.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients are treated with three cycles of oxaliplatin and fluorouracil 750 mg/m2/24 hours,&#xD;
      day 1-5. Each cycle lasts for 21 days. Oxaliplatin is given with 130 mg/m2 in the first cycle&#xD;
      and in cycle 2 and 3 which are administered concomitant with radiotherapy the dose is reduced&#xD;
      to 85 mg/m2.&#xD;
&#xD;
      A loading dose of cetuximab 400 mg/m2 is given one week before the start of radiotherapy, and&#xD;
      thereafter 250 mg/m2 is given weekly during the course of radiotherapy.&#xD;
&#xD;
      Concomitant with chemotherapy radiotherapy to a total dose of 50 Gy is given (2 Gy once daily&#xD;
      in 25 fractions, 5 days a week) with a photon beam linear accelerator.&#xD;
&#xD;
      After treatment patients are followed every 6 months for three years with clinical&#xD;
      examination and a CT-scan.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local tumour Control</measure>
    <time_frame>1 year</time_frame>
    <description>Local tumour control will be measured with a computed tomography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>3 years</time_frame>
    <description>Tumour respons evaluation with CT-scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>3 years</time_frame>
    <description>Toxicity will be measured with the Common Toxicity Criteria Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patterns of relapse</measure>
    <time_frame>3 years</time_frame>
    <description>First site of recurrence will be evaluated with CT, supplemented with biopsy if indicated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall and disease-free survival</measure>
    <time_frame>3 years</time_frame>
    <description>Tumour respons evaluation with CT scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>3 years</time_frame>
    <description>Quality of life assessed with the EORTC QLQ-C30 questionnaire.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Esophageal Neoplasm</condition>
  <arm_group>
    <arm_group_label>Cetuximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cetuximab is administered once a week. The initial dose is 400 mg/m2 body surface area. First Cetuximab infusion should start day 15 in cycle 1.The subsequent weekly doses are 250 mg/m2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <arm_group_label>Cetuximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological verified squamos cell carcinoma or adenocarcinoma of the oesophagus or&#xD;
             cardia&#xD;
&#xD;
          -  Performance status WHO 0-2, age 18-75 years&#xD;
&#xD;
          -  Locally advanced disease, non-resectable (T4 N0-N3 M0) or disease which is not&#xD;
             operable for any other reason (T2/T3 N0-N3 M0)&#xD;
&#xD;
          -  Adequate hematological, liver and renal function&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Distant metastases&#xD;
&#xD;
          -  Prior chemotherapy or radiotherapy for oesophageal cancer or cancer of the cardia&#xD;
&#xD;
          -  Symptomatic peripheral neuropathy equal to or greater than NCI grade 2&#xD;
&#xD;
          -  Other concomitant serious illness or medical condition that would not permit the&#xD;
             patient to complete the study treatment or sign the informed consent&#xD;
&#xD;
          -  Myocardial infarction within 6 months prior to study entry&#xD;
&#xD;
          -  Second primary malignancy (except in situ carcinoma of the cervix or adequately&#xD;
             treated basal cell carcinoma of the skin) unless treated, in remission and off active&#xD;
             treatment for greater than 2 years&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gabriella A von Döbeln, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska University Hospital</affiliation>
  </overall_official>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>December 15, 2015</study_first_submitted>
  <study_first_submitted_qc>December 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2015</study_first_posted>
  <last_update_submitted>September 20, 2018</last_update_submitted>
  <last_update_submitted_qc>September 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska University Hospital</investigator_affiliation>
    <investigator_full_name>Gabriella Alexandersson von Döbeln</investigator_full_name>
    <investigator_title>Medical doctor</investigator_title>
  </responsible_party>
  <keyword>Phase II study, clinical trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>September 2, 2021</submitted>
    <returned>September 30, 2021</returned>
    <submitted>October 3, 2021</submitted>
    <returned>November 1, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

